EP3724221A1 - Variants avec fragment fc ayant une affinité augmentée pour fcrn et une affinité augmentée pour au moins un récepteur du fragment fc - Google Patents
Variants avec fragment fc ayant une affinité augmentée pour fcrn et une affinité augmentée pour au moins un récepteur du fragment fcInfo
- Publication number
- EP3724221A1 EP3724221A1 EP18829783.2A EP18829783A EP3724221A1 EP 3724221 A1 EP3724221 A1 EP 3724221A1 EP 18829783 A EP18829783 A EP 18829783A EP 3724221 A1 EP3724221 A1 EP 3724221A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- variant
- fragment
- cells
- receptor
- parent polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/04—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from milk
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- Fc fragment variants having increased affinity for FcRn and increased affinity for at least one Fc receptor
- the present invention relates to a polypeptide (also called variant) comprising a mutated Fc region and having increased affinity for the FcRn receptor as well as increased affinity for at least one Fc receptor (FcR) relative to a parent polypeptide .
- An antibody consists of a tetramer of heavy and light chains.
- the two light chains are identical to each other, and the two heavy chains are identical and connected by disulfide bridges.
- There are five types of heavy chains (alpha, gamma, delta, epsilon, mu), which determine immunoglobulin classes (IgA, IgG, IgD, IgE, IgM).
- the light chain group includes two subtypes, lambda and kappa.
- IgGs are soluble antibodies that can be found in blood and other body fluids.
- IgG is a Y-shaped glycoprotein with an approximate molecular weight of 150 kDa, consisting of two heavy and two light chains. Each chain stands out in a constant region and a variable region. The two carboxy-terminal domains of the heavy chains form the Fc fragment, whereas the amino-terminal domains of the heavy and light chains recognize the antigen and are named Fab fragment.
- the Fc fusion proteins are created by a combination of an antibody Fc fragment with a protein domain that provides the specificity for a given therapeutic target. Examples are combinations of the Fc fragment with any type of therapeutic proteins or fragments thereof.
- Fc polypeptides including Fc fragments, therapeutic antibodies and Fc fusion proteins, are used today to treat various diseases, such as rheumatoid arthritis, psoriasis, multiple sclerosis and many forms of cancer.
- Therapeutic antibodies can be monoclonal or polyclonal antibodies.
- the monoclonal antibodies are obtained from a single antibody producing cell line, which shows identical specificity for a single antigen.
- the therapeutic Fc fusion proteins are used or developed as drugs against autoimmune diseases and / or inflammatory component, such as etanercept (Amgen's Enbrel, which is a Fc-bound TNF receptor) or Alefacept (Biogen Idea's Amevive, which is LFA-3 linked to the Fc portion of human IgGI).
- the Fc polypeptides such as the Fc fragments, the Fc antibodies and fusion proteins, have, in particular, an activity dependent on the binding of their Fc part to their receptors, namely FcRn and the Fc fragment receptors (FcR), such as Fc ⁇ RI receptors (CD64), Fc ⁇ RI 1a (CD16a) and Fc ⁇ RIla (CD32a).
- Fc-based therapies can act by blocking Fc receptors and thus by competing with autoantibodies for access to these receptors. This results in inhibition of direct activities normally mediated by autoantibodies (e.g., antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, or antibody-dependent cellular phagocytosis) and decreased activation of the immune system, including cytokine release.
- autoantibodies e.g., antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, or antibody-dependent cellular phagocytosis
- FcRn receptor is involved in the recycling of antibodies, blocking them with Fc polypeptides allows faster elimination of autoantibodies, thus reducing their half-life. This is why treatments based on Fc fragments are particularly suitable for autoimmune and / or inflammatory diseases, triggered by uncontrolled stimulation of the cells of the immune system, in particular by autoantibodies and / or cytokines.
- IglV intravenous immunoglobulin
- IgG intravenously immunoglobulins
- Fc fragments have been developed for the purpose of modifying their Fc receptor binding properties. Nevertheless, their effectiveness remains to be demonstrated. There is still a need to optimize these Fc fragments, in particular to increase their half-life time, and / or their therapeutic efficacy.
- Fc fragments exhibiting improved activity, in particular by an improved FcRn binding affinity. These Fc fragments can be used in therapy, and are particularly suitable for the treatment of inflammatory and / or autoimmune diseases, in order to bring greater effectiveness to the product that contains them.
- these fragments may exhibit a more efficient blockade of Fc receptors present on the cells of the immune system, which are then less, or no longer, accessible for the binding of autoantibodies, whose activity is then inhibited.
- Fc fragments make it possible to block the FcRn receptor more efficiently and thus to eliminate autoantibodies more quickly.
- Fc fragments have, as demonstrated by example, better inhibition of complement-dependent cytotoxicity (CDC) than IVIG. They would therefore make it possible to reduce the toxicity of pathogenic autoantibodies, such as those involved in inflammatory and / or autoimmune diseases.
- CDC complement-dependent cytotoxicity
- the present invention thus provides a variant of a parent polypeptide having optimized properties relating to functional activity mediated by the Fc region.
- the present invention thus relates to a variant of a parent polypeptide comprising an Fc fragment, said variant having an increased affinity for the FcRn receptor, and an increased affinity for at least one Fc receptor (FcR) selected from Fc ⁇ RI receptors.
- FcR Fc receptor
- CD64 Fc ⁇ RI1a
- CD32a Fc ⁇ RIla
- the variant according to the invention further comprises at least one mutation (iii) in the Fc fragment chosen from Y296W, K290G, V240H, V240I, V240M, V240N, V240S, F241H, F241Y, L242A, L242F, L242G, L242H, L242I, L242K, L242P, L242S, L242T, L242V, F243L, F243S, E258G, E258I, E258R, E258M, E258Q, E258Y, V259C, V259I, V259L, T260A, T260H, T260I, T260M, T260N, T260R, T260S, T260W, V262S, V263T, V264L, V264S, V264T, V266L, S267A, S267Q, S267V, K290D, K290E, K
- variant according to the invention variant according to the invention
- mutant according to the invention mutant according to the invention
- polypeptide according to the invention polypeptide according to the invention
- the variant according to the invention has both an increased affinity for the FcRn receptor and an increased affinity for all Fc ⁇ RI (CD64), Fc ⁇ RIIIa (CD16 ⁇ ) and Fc ⁇ RIla (CD32 ⁇ ) receptors.
- the variant according to the invention is capable of inhibiting complement-dependent cytotoxicity (CDC), attributed to a modification of binding to complement proteins, in particular C1 q.
- CDC complement-dependent cytotoxicity
- the variant according to the invention is different from the variant consisting of a Fc fragment, in particular of IgGI, having the five mutations N434Y, K334N, P352S, V397M and A378V, and produced in HEK293 cells, the numbering being that of EU index or equivalent in Kabat.
- the variant according to the invention is different from the Fc fragment, in particular IgGI, N434Y / K334N / P352S / V397M / A378V produced in HEK293 cells, the numbering being that of the EU index or equivalent in Kabat.
- the numbering of residues in the Fc region is that of the immunoglobulin heavy chain according to the EU index or equivalent in Kabat et al. (Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, Maryland, 1991).
- EU index or equivalent in Kabat refers to the US numbering of the residues of the human IgG1, IgG2, IgG3 or IgG4 antibody. This is illustrated on the IMGT website (http: //www.imat.ora/IMGTScientificChart/Numberina/Hu IGHGnber.html).
- polypeptide or “protein” is meant a sequence comprising at least 100 amino acids covalently attached.
- amino acid is meant one of the 20 naturally occurring amino acids or unnatural analogues.
- the term "position” means a position in the sequence of a polypeptide. For the Fc region, the positions are numbered according to the EU index or equivalent in Kabat.
- the term “antibodies” is used in the common sense. It corresponds to a tetramer that includes at least one Fc region, and two variable regions. Antibodies include, but are not limited to, full-length immunoglobulins, monoclonal antibodies, multi-specific antibodies, chimeric antibodies, humanized antibodies, and fully human antibodies.
- the amino-terminal portion of each heavy chain comprises a variable region of about 100 to 10 amino acids responsible for antigen recognition. In each variable region, three loops are pooled to form an antigen binding site. Each of the loops is called a complementarity determining region (hereinafter referred to as a "CDR").
- CDR complementarity determining region
- IgGs have several subclasses, including IgG1, IgG2, IgG3 and IgG4.
- the subclasses of IgM are in particular IgM1 and IgM2.
- isotype is meant one of the subclasses of immunoglobulins defined by the chemical and antigenic characteristics of their constant regions.
- the known isotypes of human immunoglobulins are IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgM1, IgM2, IgD and IgE.
- Full length IgGs are tetramers and consist of two identical pairs of two immunoglobulin chains, each pair having a light chain and a heavy chain, each light chain comprising the VL and CL domains, and each heavy chain comprising the VH domains.
- Cy1 also called CH1
- Cy2 also called CH2
- Cy3 also called CH3
- CH1 refers to positions 1-18 to 215
- CH2 refers to positions 231 to 340
- CH3 refers to positions 341 to 447 according to the EU index or equivalent in Kabat .
- the IgG heavy chain also includes an N-terminal flexible hinge domain which refers to positions 216-230 in the case of IgGI.
- the lower hinge range refers to positions 226 to 230 according to the EU index or equivalent in Kabat.
- variable region is meant the region of an immunoglobulin which comprises one or more Ig domains substantially encoded by any of the VK, VA and / or VH genes that make up the kappa, lambda, and immunoglobulin heavy chains. , respectively.
- Variable regions include complementarity determining regions (CDRs) and framework regions (FRs).
- Fc or "Fc region” refers to the constant region of an antibody excluding the first immunoglobulin constant region (CH1) domain.
- Fc refers to the last two domains (CH2 and CH3) of IgGI constant region, and to the flexible N-terminal hinge of these domains.
- the Fc region corresponds to the residue C226 to its carboxy terminal end, ie the residues of the position 226 to 447, where the numbering is according to the EU index or equivalent in Kabat.
- the Fc region used may further comprise a portion of the upper hinge region located between positions 216-226 according to the EU index or equivalent in Kabat; in this case, the Fc region used corresponds to the residues of heading 216 to 447, 217 to 447, 218 to 447, 219 to 447, 220 to 447, 221 to 447, 222 to 447, 223 to 447, 224 to 447 or 225 to 447, where the numbering is according to the EU index or equivalent in Kabat.
- the Fc region used corresponds to the residues of position 216 to 447, where the numbering is according to the EU index or equivalent in Kabat.
- the Fc region used is chosen from the sequences SEQ ID NO: 1 to 10 and 14.
- parent polypeptide is meant a reference polypeptide.
- the said parent polypeptide may be of natural or synthetic origin.
- the parent polypeptide comprises an Fc region, referred to as the "parent Fc region". This Fc region may be selected from the group of wild-type Fc regions, their fragments and mutants.
- the parent polypeptide comprises a human Fc fragment, preferably an Fc fragment of a human IgG1 or a human IgG2.
- the parent polypeptide may include preexisting amino acid modifications in the Fc region (eg, Fc mutant) relative to wild type Fc regions.
- the parent polypeptide is an isolated Fc region (ie an Fc fragment as such), a sequence derived from an isolated Fc region, an antibody, an antibody fragment comprising an Fc region, a fusion protein comprising a Fc region or a conjugate Fc, this list not being limiting.
- sequence derived from an isolated region Fc is meant a sequence comprising at least two isolated Fc regions linked together, such as a scFc (single chain Fc) or a multimer Fc.
- fusion protein comprising an Fc region is meant a polypeptide sequence fused to an Fc region, said polypeptide sequence being preferably selected from variable regions of any antibody, receptor binding sequences to its ligand, adhesion molecules, ligands, enzymes, cytokines and chemokines.
- Fc conjugate is meant a compound which is the result of the chemical coupling of an Fc region with a conjugation partner.
- the conjugation partner may be protein or non-protein.
- the coupling reaction generally utilizes functional groups on the Fc region and the conjugation partner.
- Various linking groups are known in the art as being suitable for the synthesis of a conjugate; for example, homo-or heterobifunctional linkers are well known (see, Pierce Chemical Company catalog, 2005-2006, technical section on crosslinking agents, pages 321-350).
- Suitable conjugation partners include therapeutic proteins, labels, cytotoxic agents such as chemotherapeutic agents, toxins and their active fragments. Suitable toxins and fragments thereof include diphtheria toxin, exotoxin A, ricin, abrin, saporin, gelonin, calicheolyin, auristatin E and F, and mertansin.
- the parent polypeptide - and therefore the polypeptide according to the invention - consists of an Fc region.
- the parent polypeptide - and therefore the polypeptide according to the invention - is an antibody.
- mutation is meant a change of at least one amino acid of the sequence of a polypeptide, including a change of at least one amino acid of the Fc region of the parent polypeptide.
- the mutated polypeptide thus obtained is a variant polypeptide; it is a polypeptide according to the invention.
- Such a polypeptide comprises a mutated Fc region, relative to the parent polypeptide.
- the mutation is a substitution, an insertion or a deletion of at least one amino acid.
- substitution is meant the replacement of an amino acid at a particular position in a parent polypeptide sequence by another amino acid.
- the N434S substitution refers to a variant polypeptide, in this case a variant for which asparagine at position 434 is replaced by serine.
- amino acid insertion or “insertion” is meant the addition of an amino acid at a particular position in a parent polypeptide sequence.
- insertion G> 235-236 refers to a glycine insertion between positions 235 and 236.
- amino acid deletion or “deletion” is meant the deletion of an amino acid at a particular position in a parent polypeptide sequence.
- E294del refers to the removal of glutamic acid at position 294.
- the following mutation label is used: "434S” or “N434S”, and means that the parent polypeptide comprises asparagine at position 434, which is replaced by serine in the variant.
- the preferred format is "259I / 315D / 434Y” or "V259I / N315D / N434Y”.
- FcRn or “neonatal Fc receptor” as used herein is meant a protein that binds to the Fc region of IgG and is encoded at least in part by a FcRn gene.
- the functional FcRn protein comprises two polypeptides, often referred to as heavy chain and light chain.
- the light chain is beta-2-microglobulin and the heavy chain is encoded by the FcRn gene.
- FcRn or FcRn protein refers to the ⁇ -chain complex with beta-2-microglobulin.
- the gene encoding FcRn is called FCGRT.
- the variant according to the invention has an increased affinity for the FcRn receptor, relative to that of the parent polypeptide, of a ratio at least equal to 2, preferably greater than 5, preferably greater than 10, preferably greater than 15, preferably greater than 20, preferably greater than 25, preferably greater than 30.
- the variant according to the invention has an increased half-life compared to that of the parent polypeptide.
- the variant according to the invention has an increased half-life with respect to that of the parent polypeptide, of a ratio at least equal to 2, preferably greater than 5, preferably greater than 10, preferably greater than 15. preferably greater than 20, preferably greater than 25, preferably greater than 30.
- IgG recycling One of the major functions of FcRn is known as IgG recycling. It consists of extracting IgG from the endothelial catabolism pathway of plasma proteins to restore them intact to the circulation. This recycling explains their half-life under normal physiological conditions (three weeks for IgG), while maintaining high plasma concentrations.
- the transcytosis of IgG from one pole to the other of epithelia or endothelium is the second major function of FcRn to ensure their biodistribution in the body.
- the variant according to the invention has an increased affinity for at least one receptor of the Fc fragment (FcR) chosen from the receptors Fc ⁇ RI (CD64), Fc ⁇ RIIIa (CD16 ⁇ ) and Fc ⁇ RIla (CD32 ⁇ ), with respect to that of the parent polypeptide. , a ratio at least equal to 2, preferably greater than 5, preferably greater than 10, preferably greater than 15, preferably greater than 20, preferably greater than 25, preferably greater than 30.
- FcR Fc fragment
- the Fc ⁇ RI receptor (CD64) is involved in phagocytosis and cell activation.
- the Fc ⁇ RIIIa receptor (CD16a) is also involved in Fc-dependent activity, including ADCC and phagocytosis; it has a V / F polymorphism at position 158.
- the Fc? RIIa receptor (CD32a) is, in turn, involved in platelet activation and phagocytosis; it has an H / R polymorphism at position 131.
- the variant according to the invention has both an increased affinity for the FcRn receptor and an increased affinity for all Fc ⁇ RI (CD64), Fc ⁇ RIIIa (CD16 ⁇ ) and Fc ⁇ RIla (CD32 ⁇ ) receptors.
- the affinity of a polypeptide comprising an Fc region for a FcR can be evaluated by methods well known in the art. For example, one skilled in the art can determine affinity (Kd) using surface plasmon resonance (SPR). Alternatively, one skilled in the art can perform an appropriate ELISA test. An appropriate ELISA assay compares the binding forces of the parent Fc and the mutated Fc. The detected signals specific for the mutated Fc and the parent Fc are compared. Binding affinity can be indifferently determined by evaluating whole polypeptides or evaluating isolated Fc regions thereof. Alternatively, one skilled in the art can perform an appropriate competitive test.
- An appropriate competitive assay is used to determine the ability of the mutated Fc to inhibit the binding of a labeled FcR ligand when these are incubated simultaneously with cells expressing these receptors.
- the binding of the labeled ligand to FcR is evaluated for example by flow cytometry.
- the binding affinity of the Fc mutated at FcR is then determined by evaluating the variability of the average fluorescence intensity emitted by the labeled ligand bound to FcR.
- the mutated Fc region of the polypeptide according to the invention comprises from 3 to 20 mutations relative to the parent polypeptide, preferably from 4 to 20 mutations.
- from 3 to 20 amino acid modifications is meant 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 and Amino acid mutations.
- it comprises from 4 to 15 mutations, preferably from 4 to 10 mutations relative to the parent polypeptide.
- the mutated Fc region of the polypeptide according to the invention comprises at least one combination of 5 mutations, said combination comprising the four mutations (i) as described above, and at least one mutation (ii) as described herein. above the numbering being that of the EU index or equivalent in Kabat.
- the mutated Fc region of the polypeptide according to the invention comprises a combination of 6 mutations, said combination comprising the four mutations (i) as described above, at least one mutation (ii) as described above, and at least one mutation (iii) as described above, the numbering being that of the EU index or equivalent in Kabat.
- the mutated Fc region of the polypeptide according to the invention comprises the following mutations:
- mutation (iii) when mutation (iii) is present, it is selected from K290G and Y296W,
- the mutated Fc region of the polypeptide according to the invention comprises the following mutations:
- the mutated Fc region of the polypeptide according to the invention comprises a combination of mutations chosen from the combinations: N434Y / K334N / P352S / V397M / A378V and N434Y / K334N / P352S / V397M / A378V / Y296W.
- the polypeptide according to the invention is produced in mammary epithelial cells of transgenic non-human mammals.
- the polypeptide according to the invention is produced in non-human transgenic animals, preferably in transgenic non-human mammals, more preferably in their mammary epithelial cells.
- transgenic non-human mammal is meant a mammal chosen in particular from cattle, pigs, goats, sheep and rodents, preferably from the goat, the mouse, the sow, the rabbit, the ewe and the cow.
- the non-human transgenic animal or the non-human transgenic mammal is a transgenic goat.
- the variant according to the invention comprises at least the five mutations N434Y, K334N, P352S, V397M and A378V in its Fc fragment, and is produced in mammary epithelial cells of transgenic non-human mammals, or in transgenic non-transgenic animals. humans, preferably in transgenic non-human mammals, such as a goat.
- Such a variant has both increased affinity for the FcRn receptor, and increased affinity for all Fc ⁇ RI (CD64), Fc ⁇ RI1a (CD16a) and Fc ⁇ RIla (CD32a) receptors.
- the variant according to the invention is the Fc N434Y / K334N / P352S / V397M / A378V variant produced in mammary epithelial cells of transgenic non-human mammals.
- the variant according to the invention is the Fc N434Y / K334N / P352S / V397M / A378V variant produced in non-human transgenic animals, preferably in transgenic non-human mammals, such as a goat.
- Such a variant has both increased affinity for the FcRn receptor, and increased affinity for all Fc ⁇ RI (CD64), Fc ⁇ RIIIa (CD16 ⁇ ) and Fc ⁇ RIla (CD32 ⁇ ) receptors.
- the variant according to the invention comprises the sequence SEQ ID NO: 1 1 or the sequence SEQ ID NO: 15.
- the variant according to the invention is the variant Fc N434Y / K334N / P352S / V397M / A378V / Y296W produced in epithelial cells. mammals of transgenic non-human mammals.
- the variant according to the invention is the Fc N434Y / K334N / P352S / V397M / A378V / Y296W variant produced in non-human transgenic animals, preferably in transgenic non-human mammals, such as a goat.
- Such a variant has both increased affinity for the FcRn receptor, and increased affinity for all Fc ⁇ RI (CD64), Fc ⁇ RIIIa (CD16 ⁇ ) and Fc ⁇ RIla (CD32 ⁇ ) receptors.
- the method for producing a variant according to the invention comprises the expression of said variant in mammary epithelial cells of transgenic non-human mammals.
- the present invention also relates to a method for producing a variant of a parent polypeptide comprising an Fc fragment, said variant having an increased affinity for the FcRn receptor, and an increased affinity for at least one Fc receptor (FcR) selected from FcyRI (CD64), Fc ⁇ RIIIa (CD16a) and Fc ⁇ RIla (CD32a) receptors, relative to that of the parent polypeptide, said variant comprising:
- said method comprising expressing said variant in mammary epithelial cells of transgenic non-human mammals.
- said variant further comprises at least one mutation (iii) in the Fc fragment chosen from Y296W, K290G, V240H, V240I, V240M, V240N, V240S, F241H, F241Y, L242A, L242F, L242G, L242H, L242I, L242K, L242P, L242S, L242T,
- V259L T260A, T260H, T260I, T260M, T260N, T260R, T260S, T260W, V262S, V263T,
- such a method comprises the following steps:
- a) preparing a DNA sequence comprising a sequence encoding the variant, a sequence encoding a mammalian casein promoter or a mammalian whey promoter, and a sequence encoding a signal peptide permitting the secretion of said variant;
- Step a) thus comprises the preparation of a DNA sequence comprising a sequence coding for the variant, a sequence coding for a mammalian casein promoter or a mammalian whey promoter, and a sequence coding for a signal peptide. allowing the secretion of said variant.
- a DNA sequence comprising a sequence coding for the variant, a sequence coding for a mammalian casein promoter or a mammalian whey promoter, and a sequence coding for a signal peptide.
- the sequence coding for the variant is a DNA sequence coding for the variant according to the invention.
- this variant has the sequence SEQ ID NO: 1 1.
- the corresponding sequence is the sequence SEQ ID NO: 13.
- this variant has the sequence SEQ ID NO: 15. With the signal peptide, the corresponding sequence is the sequence SEQ ID NO: 16.
- the coding sequence for a mammalian casein promoter or a mammalian whey promoter makes it possible to express the variant in the milk.
- the person skilled in the art knows how to choose such a promoter.
- a signal peptide is an amino acid sequence, preferably from 2 to 30 amino acids, located at the N-terminus of the Fc polypeptide variant, serving to address it in the mammalian milk.
- the coding sequence for a signal peptide is interposed between the sequence coding for the variant and the promoter. Without such a sequence, the variant would remain in the breast tissue, and purification would be difficult and would require the sacrifice of the host animal.
- the signal peptide can be cleaved upon secretion.
- the coding sequence for the peptide signal may be one that is naturally associated with a parent polypeptide according to the invention.
- the coding sequence for the signal peptide may be that of the milk protein from which the promoter is derived, ie, when the milk protein gene is digested in order to isolate the promoter, a DNA fragment is selected comprising both the promoter and the coding sequence the signal peptide directly downstream of the promoter.
- Another alternative is to use a signal sequence derived from another secreted protein that is neither the milk protein normally expressed from the promoter nor a polypeptide according to the invention.
- the signal peptide has the sequence SEQ ID NO: 12.
- the DNA sequence used may comprise optimized codons.
- Codon optimization aims to replace natural codons by codons whose transfer RNA (tRNA) carrying the amino acids are most common in the cell type considered.
- tRNA transfer RNA
- the mobilization of frequently encountered tRNAs has the major advantage of increasing the translation speed of messenger RNAs (mRNAs) and therefore of increasing the final titre (JM Carton et al., Protein Expr Purif, 2007).
- Sequence optimization also plays on the prediction of mRNA secondary structures that could slow down reading by the ribosomal complex. Sequence optimization also has an impact on the percentage of G / C that is directly related to the half-life of the mRNAs and therefore to their potential to be translated (Chechetkin, J. of Theoretical Biology 242, 2006 922-934 ).
- Codon optimization can be done by substitution of natural codons using codon frequency (Codon Usage Table) tables for mammals and more specifically for Homo sapiens.
- codon frequency Codon Usage Table
- step a) is comprised of the following steps:
- step a there is obtained a DNA sequence comprising, from the N- to C-terminal end, the coding sequence for a mammalian casein promoter or a mammalian whey promoter, fused to the coding sequence for a signal peptide, itself fused to the coding sequence for the variant according to the invention.
- the method according to the invention comprises a step b) of introducing the DNA sequence obtained in a) into a non-human mammalian embryo, in order to obtain a transgenic non-human mammal expressing the variant coded by said sequence. of DNA obtained in a) in the mammary gland.
- the method according to the invention comprises a step c) of recovering the variant in the milk produced by the transgenic nonhuman mammal obtained in b).
- Steps b) and c) are known from the prior art, in particular patent EP0264166.
- such a process comprises, after step c), a purification step d) recovered milk.
- the purification step d) can be carried out by any known method of the prior art, in particular by purification on protein A.
- a step is described in particular in patent EP0264166.
- the present invention also relates to a DNA sequence comprising a gene encoding a variant of a parent polypeptide comprising an Fc fragment, said variant having an increased affinity for the FcRn receptor, and an increased affinity for at least one fragment receptor.
- Fc (FcR) selected from Fc ⁇ RI (CD64), Fc ⁇ RIIIa (CD16 ⁇ ) and Fc ⁇ RIla (CD32 ⁇ ) receptors, relative to that of the parent polypeptide, said variant comprising:
- said gene being under the control of a transcriptional promoter of casein or mammalian whey which does not naturally control the transcription of said gene, said DNA sequence further comprising a sequence coding for a signal peptide allowing the secretion of said variant interposed between the sequence encoding the variant and the promoter.
- said variant further comprising at least one mutation (iii) in the Fc fragment chosen from Y296W, K290G, V240H, V240I, V240M, V240N, V240S, F241H, F241 Y, L242A, L242F, L242G , L242H, L242I, L242K, L242P, L242S, L242T, L242V, F243L, F243S, E258G, E258I, E258R, E258M, E258Q, E258Y, V259C, V259I, V259L, T260A, T260H, T260I, T260M, T260N, T260R, T260S , T260W, V262S, V263T, V264L, V264S, V264T, V266L, S267A, S267Q, S267V, K290D, K290E,
- the present invention also relates to a DNA sequence comprising a gene encoding a variant of a parent polypeptide comprising an Fc fragment, said variant having an increased affinity for the FcRn receptor, and an increased affinity for at least one fragment receptor.
- Fc (FcR) selected from Fc ⁇ RI (CD64), Fc ⁇ RIIIa (CD16 ⁇ ) and Fc ⁇ RIla (CD32 ⁇ ) receptors, relative to that of the parent polypeptide, said variant comprising:
- said DNA sequence optionally comprising a sequence encoding a signal peptide permitting the secretion of said variant.
- said variant further comprising at least one mutation (iii) in the Fc fragment chosen from Y296W, K290G, V240H, V240I, V240M, V240N, V240S, F241H, F241 Y, L242A, L242F, L242G , L242H, L242I, L242K, L242P, L242S, L242T, L242V, F243L, F243S, E258G, E258I, E258R, E258M, E258Q, E258Y, V259C, V259I, V259L, T260A, T260H, T260I, T260M, T260N, T260R, T260S, T260W, V262S, V263T, V264L, V264S, V264T, V266L, S267A, S267Q, S267V, K290D, K290E, K
- the polypeptide according to the invention can be produced in cultured mammalian cells.
- the preferred cells are the YB2 / 0 rat line, the CHO hamster line, in particular the CHO dhfr- and CHO Lec13 lines, the PER cells.
- the CHO hamster line is used.
- the present invention also relates to a method for producing a variant of a parent polypeptide comprising an Fc fragment, said variant having an increased affinity for the FcRn receptor, and an increased affinity for at least one Fc receptor (FcR) selected from FcyRI (CD64), Fc ⁇ RI1a (CD16a) and Fc ⁇ RIla (CD32a) receptors, relative to that of the parent polypeptide, said variant comprising:
- said method comprising expressing said variant in mammalian cells in culture.
- said variant further comprising at least one mutation (iii) in the Fc fragment chosen from Y296W, K290G, V240H, V240I, V240M, V240N, V240S, F241H, F241 Y, L242A, L242F, L242G , L242H, L242I, L242K, L242P, L242S, L242T, L242V, F243L, F243S, E258G, E258I, E258R, E258M, E258Q, E258Y, V259C, V259I, V259L, T260A, T260H, T260I, T260M, T260N, T260R, T260S , T260W, V262S, V263T, V264L, V264S, V264T, V266L, S267A, S267Q, S267V, K290D, K290E,
- such a method comprises the following steps:
- the introduction can be carried out transiently or stably (i.e. integration of the DNA sequence obtained in a) into the genome of the cells);
- the present invention also relates to a pharmaceutical composition
- a pharmaceutical composition comprising (i) a polypeptide according to the invention, and (ii) at least one pharmaceutically acceptable excipient.
- the subject of the present invention is also a pharmaceutical composition
- a pharmaceutical composition comprising (i) the variant consisting of an Fc fragment, in particular of IgGI, exhibiting the five mutations N434Y, K334N, P352S, V397M and A378V, the numbering being that of the EU index. or equivalent in Kabat, and (ii) at least one pharmaceutically acceptable excipient.
- the composition of the present invention comprises (i) the variant consisting of an Fc fragment, in particular of IgGI, having the six mutations N434Y, K334N, P352S, V397M and A378V, Y296W, the numbering being that of the index EU or equivalent in Kabat, and (ii) at least one pharmaceutically acceptable excipient.
- the subject of the present invention is also the polypeptide according to the invention or the composition as described above, for its use as a medicament.
- the subject of the present invention is also the use of the variant consisting of an Fc fragment, in particular of IgGI, exhibiting the five mutations N434Y, K334N, P352S, V397M and A378V, the numbering being that of the EU index or equivalent in Kabat. (ie variant N434Y / K334N / P352S / V397M / A378V) as a drug.
- the subject of the present invention is also the use of the variant consisting of an Fc fragment, in particular of IgGI, presenting the six mutations N434Y, Y296W, K334N, P352S, V397M, A378V, and Y296W, the numbering being that of the index EU or equivalent in Kabat (ie variant N434Y / K334N / P352S / V397M / A378V / Y296W) as a drug.
- the parent polypeptide - and therefore the polypeptide according to the invention - is an antibody.
- the antibody may be directed against an antigen selected from a tumor antigen, a viral antigen, a bacterial antigen, a fungal antigen, a toxin, a membrane or circulating cytokine and a membrane receptor.
- cancer When the antibody is directed against a tumor antigen, its use is particularly suitable in the treatment of cancers.
- cancer is meant any physiological condition characterized by an abnormal proliferation of cells. Examples of cancers include carcinomas, lymphomas, blastomas, sarcomas (including liposarcomas), neuroendocrine tumors, mesotheliomas, meningiomas, adenocarcinomas, melanomas, leukemias and lymphoid malignancies. not being exhaustive.
- Viral infections include infections caused by HIV, a retrovirus, a Coxsackie virus, smallpox virus, influenza, yellow fever, West Nile, a cytomegalovirus, a rotavirus or hepatitis B or C, this list is not exhaustive.
- the antibody When the antibody is directed against a toxin, its use is particularly useful in the treatment of bacterial infections, for example infections with tetanus toxin, diphtheria toxin, anthrax toxins Bacillus anthracis, or in the treatment of infections by botulinum toxins, ricin toxins, shigatoxins, this list is not exhaustive.
- Inflammatory and / or autoimmune diseases include thrombotic thrombocytopenic purpura (ITP), transplant and organ rejection, graft-versus-host disease, rheumatoid arthritis, systemic lupus erythematosus, various types of sclerosis, primary Sjögren's syndrome (or Sjögren's syndrome), autoimmune polyneuropathies such as multiple sclerosis, type I diabetes, autoimmune hepatitis, ankylosing spondylitis, Reiter's syndrome, gout arthritis, celiac disease, Crohn's disease, Hashimoto chronic thyroiditis (hypothyroidism), Adisson's disease, autoimmune hepatitis, Basedow (hyperthyroidism), ulcerative colitis, vasculitis and systemic vasculitis associated with ANCA (anti-cytoplasmic antibodies to neutrophils),
- ITP thrombotic thrombocytopenic purpura
- transplant and organ rejection graft-versus-host disease
- the child including antiphospholipid syndrome, connective tissue disease, pulmonary autoimmune inflammation, Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy (PDCI), autoimmune thyroiditis, mellitis, myasthenia gravis , inflammatory autoimmune disease of the eye, optic neuromyelitis (Devia's disease), scleroderma, pemphigus, insulin resistance diabetes, polymyositis, Biermer's anemia, glomerulonephritis, Wegener's disease, Horton, periarthritis nodosa and Churg and Strauss syndrome, Still's disease, atrophic polychondritis, malaise of Behçet, monoclonal gammopathy, Wegener's granulomatosis, lupus, ulcerative colitis, psoriatic arthritis, sarcoidosis, collagenous colitis, dermatitis herpetiformis, familial Mediterranean fever, IgA glomerulonephritis
- inflammatory diseases are also understood, such as acute respiratory distress syndrome (ARDS), acute septic arthritis, adjuvant arthritis, allergic encephalomyelitis, allergic rhinitis, allergic vasculitis, allergy, asthma, atherosclerosis, chronic inflammation due to chronic bacterial or viral infections, chronic obstructive pulmonary disease (COPD), coronary heart disease, encephalitis, inflammatory bowel disease, inflammatory osteolysis, inflammation associated with acute and delayed hypersensitivity reactions, inflammation associated with tumors, peripheral nerve injury or demyelinating diseases, inflammation associated with tissue trauma such as burns and ischemia, inflammation due to meningitis, multiorgan organ failure syndrome (multiple organ dysfunction syndrome, MODS), pulmonary fibrosis, sepsis and septic shock, Stevens-Johnson syndrome, undifferentiated arthritis, and undifferentiated spondyloarthropathies.
- the autoimmune disease is idiopathic thrombotic purpura (ITP) and chronic inflammatory demyelinating poly
- the autoimmune or inflammatory pathology is selected from immunologic thrombocytopenic purpura (also called idiopathic thrombocytopenic purpura, or ITP), optic neuromyelitis or deviant disease (OMN) and multiple sclerosis.
- ITP immunologic thrombocytopenic purpura
- OPN optic neuromyelitis or deviant disease
- multiple sclerosis Multiple sclerosis and in particular studied thanks to a model of experimental autoimmune encephalomyelitis (EAE).
- Figure 1 Production of variant A3A-184AY in goat milk and mouse using the vector Bc451
- the NotI-NotI fragment is the prokaryotic fragment.
- the NotI fragment (15730) - XhoI is the 3 'genomic sequence that contains the polyA signal.
- BamHI - XhoI is the promoter region of beta casein.
- the disease was induced by transferring 10 mI of K / BxN mouse serum intravenously on day 0 to C57 / BI / 6J mice.
- the test molecules were administered once intraperitoneally at 0 h 2h before injection of K / BxN mouse serum.
- the clinical score is obtained by summing the four-legged index:
- 0 normal
- 1 swelling of a joint
- 2 swelling of more than one joint
- 3 severe swelling of the entire joint (arbitrary units or arbitrary units).
- Figure 3 Results of tests in a therapeutic model of arthritis induced by the transfer of K / BxN mouse serum
- the disease was induced by transferring 10 mI of K / BxN mouse serum intravenously on day 0 to C57 / BI / 6J mice.
- the test molecules were administered once intraperitoneally at 0, 72 hours after injection of K / BxN mouse serum (indicated by dotted lines).
- the clinical score is obtained by summing the four-legged index:
- 0 normal
- 1 swelling of a joint
- 2 swelling of more than one joint
- 3 severe swelling of the entire joint (arbitrary units or arbitrary units).
- IglV or Fc variants according to the invention labeled with Alexa were incubated at 65 nM (10 ⁇ g / ml for Fc in 2% CSF PBS) with target cells for 20 minutes on ice. After 2 washes in 2% CSF, the cells were suspended in 500mI Isoflow prior to flow cytometric analysis.
- B cells labeled with anti-CD19 ("% positive B cells");
- NK cells labeled with anti-CD56 ("% positive NK cells");
- Raji cells 50mI at 5 x 10 6 cells / ml
- Rituxan 50mI to 2m9 / ml
- Jurkat cells expressing human CD64 Jurkat-H-CD64
- PMA 50 mI to 40 ng / ml
- IglV or the variant according to the invention RRC A3A-184AY
- the plates were centrifuged (125 g for 1 minute) and NL2 contained in the supernatant was evaluated by ELISA.
- Effector cells (mononuclear cells) (25 mI at 8 x 10 7 cells / ml) and Rh-positive RBCs (25 mI at 4 x 10 7 cells / ml final) were incubated with different concentrations (0 to 75 ng / ml).
- ml) of anti-Rh-antibody D with an Effector / Target ratio of 2/1.
- lysis was estimated by quantifying the hemoglobin released into the supernatant using a specific substrate (DAF).
- DAF specific substrate
- Raji cells were incubated for 30 minutes with a final concentration of 50 ng / ml of rituximab.
- a solution of young rabbit serum diluted 1/10 and previously incubated with the variant Fc according to the invention (rFc A3A-184AY) or IglV (vol / vol) for 1 h at 37 ° C. was added. After 1 hour of incubation at 37 ° C, the plates were centrifuged (125 g for 1 minute) and the CDC was estimated by measuring the intracellular LDH released in the culture medium. The results were expressed as percent inhibition and compared to IgG and negative control (Fc without Fc function, ie rFc neg), 100% corresponding to a complete inhibition of lytic activity and 0% to the control value obtained without Fc or IglV.
- IglV, Fc-Rec (wild-type Fc), Fc MST-HN or Fc variants according to the invention (A3A-184AY CHO, A3A-184EY CHO) labeled with Alexa-Fluor® were incubated at 65 nM (10 ⁇ g / ml).
- NK Natural Killer
- mice expressing humanized FcRn were induced in mice expressing humanized FcRn by injecting an anti-platelet antibody 6A6-hlgG1 (0.3pg / g body weight) intravenously to deplete platelets, also called thrombocytes, from mice.
- Negative Control (“CTL PBS"), IglV (1000 mg / kg), Fc-Rec (Fc-wild) fragment (380 and 750 mg / kg), Fc MST-HN fragment (190 mg / kg) and the variant of the invention Fc A3A-184AY CHO (190 mg / kg and 380 mg / kg), were administered intraperitoneally 2 hours before platelet depletion. Platelet count was determined with an Advia Hematology system (Bayer). The number of platelets before the injection of antibodies was set at 100%.
- An Fc fragment according to the invention can be produced in the milk of transgenic animals, by placing the coding sequence of the Fc fragment in a milk-specific expression vector.
- the vector can be introduced into the genome of a transgenic mouse or goat by microinjection. Following the screening and identification of an animal with the transgene, the females are reproduced. Following the parturition, milking the females allows to recover their milk, in which the Fc could be secreted following the expression of the specific promoter of the milk.
- a signal peptide (MRWSWIFLLLLSITSANA, SEQ ID NO: 12) is linked to the N-terminus of the protein sequence, in order to obtain the sequence SEQ ID NO: 13. It allows the secretion of the protein in milk, once expressed.
- the nucleotide sequence has been optimized for expression in the goat mammary gland.
- the sequence was optimized for the Bos taurus species by the algorithm of a synthetic gene provider (such as GeneArt).
- the goat beta casein expression vector (Bc451) was used for the production of the A3A-184AY variant in mouse and goat milk (see Figure 1).
- the beta casein vector, Bc451 was digested with XhoI (FIG. 1A).
- the SalI fragment containing the Fc A3A-184AY variant coding region was inserted to generate the BC3180 FC A3A-184AY gene construct ( Figures 1B and 1C).
- the DNA fragment for microinjection was then isolated from the prokaryotic vector.
- BC3180 was digested with NotI and NruI ( Figure 1D).
- the released 16.4kb fragment containing the Fc gene under the control of the beta casein promoter was then purified by gel elution. This DNA was then used in the microinjection stage.
- the DNA fragment was inserted by microinjection into preimplantation mouse embryos. The embryos were then implanted in pseudopregnant females. The offspring that were born were screened for the presence of the transgene by PCR analysis.
- the DNA fragment prepared for microinjection can also be used for the production of the Fc variant A3A-184AY in goat's milk.
- Each mutation of interest in the Fc fragment of sequence SEQ ID NO: 14 was inserted by overlap PCR using two sets of primers adapted to integrate the targeted mutation (s) with the codon (s). encoding the desired amino acid.
- the mutations to be inserted are close to the Fc sequence, they are added via the same oligonucleotide.
- the fragments thus obtained by PCR were combined and the resulting fragment was amplified by PCR using standard protocols.
- the PCR product was purified on 1% (w / v) agarose gel, digested with the appropriate restriction enzymes and cloned.
- the biotinylated hFcRn receptor is immobilized on Streptavidin Biosensors, diluted to 0.7 ⁇ g / ml in run buffer (0.1 M phosphate buffer, 150 mM NaCl, 0.05% Tween 20, pH6).
- run buffer 0.1 M phosphate buffer, 150 mM NaCl, 0.05% Tween 20, pH6.
- Regeneration 120s in regeneration buffer (0.1 M phosphate buffer, 150 mM NaCl, 0.05% Tween 20, pH 7.8).
- association and dissociation curves (first 10s) are used to calculate the kinetic constants of association (kon) and dissociation (koff) using a 1/1 association model. KD (nM) is then calculated (kon / koff).
- the hCD16aV (R & D System) or hCD32aH (PX therapeutics) HisTag receptor is immobilized on anti-Penta-HIS Biosensors (HIS 1 K), diluted to 1 ⁇ g / ml in kinetic buffer (Pall).
- the Fc variants according to the invention, WT and IglV, were tested at 1000, 500, 250, 125, 62.5, 31.25, 15 and 0 nM in kinetic buffer.
- Regeneration 5s in regeneration buffer (Glycine 10mM pH 1 .5 / Neutralization: PBS).
- association and dissociation curves (first 5s) are used to calculate the kinetic constants of association (kon) and dissociation (koff) using a 1/1 association model. KD (nM) is then calculated (kon / koff).
- the variant Fc A3A 184AY (HEK) according to the invention exhibits both an increased affinity for the hFcRn receptor, and an increased affinity for the Fc ⁇ RIIIa (CD16a) and Fc ⁇ RIla (CD32a) receptors, and this, compared to Fc parent not mutated (Fc-WT) but also compared to IVIG.
- K / BxN model was generated by crossing the transgenic mice for the KRN T cell receptor to the NOD mouse strain.
- K / BxN F1 mice develop spontaneously develop a disease at 3 to 5 weeks of age and share many clinical features with human rheumatoid arthritis.
- the disease was induced by transferring 10 mI of K / BxN mouse serum intravenously on day 0 to C57 / BI / 6J mice.
- the molecules tested were administered once intraperitoneally at 0, 2h before or 72 hours after the injection of K / BxN mouse serum.
- mice were monitored daily for signs and symptoms of arthritis to assess incidence and severity by adding the four-leg index:
- 0 normal
- 1 swelling of a joint
- 2 swelling of more than one joint
- 3 severe swelling of the entire joint.
- treatment with the Fc WT fragment at 750 mg / kg significantly reduced the clinical score compared to the group. treated with K / BxN mouse serum.
- treatment with the variant Fc A3A-184AY (HEK) according to the invention significantly reduced the clinical score similarly to the Fc-WT fragment, but at a dose 4-fold lower (190 mg / kg) (FIG. 3).
- IglV or Fc variants according to the invention labeled with Alexa were incubated at 65 nM (10 ⁇ g / ml for Fc in 2% CSF PBS) with target cells for 20 minutes on ice. After 2 washes in 2% CSF, the cells were suspended in 500mI Isoflow prior to flow cytometric analysis. B cells, NK cells, monocytes and neutrophils were specifically labeled with anti-CD19, anti-CD56, anti-CD14 and anti-CD15 respectively.
- the Fc ⁇ RIII receptor (CD16) was demonstrated using the anti-CD16 3G8 antibody.
- an effector cell-mediated red cell lysis in the presence of an anti-human monoclonal antibody was conducted, and the ability of different amounts of polyvalent immunoglobulins (IVIg) or mutated or non-mutated recombinant Fc fragments, to inhibit this lysis, for example by competition with anti-RhD for fixation Fc receptors on the surface of the effector cells were evaluated.
- effector cells monoonuclear cells
- Rh-positive red cells 25 to 4 x 10 7 cells / ml final
- DAF specific substrate
- results are expressed as a percentage of specific lysis as a function of the amount of antibody.
- the inhibition of ADCC induced by IglV or the Fc variant according to the invention (RFC A3A-184AY) added to 33 nM was evaluated.
- the results are expressed in percent, 100% and 0% being the values obtained with IglV at 650 nM and 0 nM respectively according to the following formula:
- This test estimates the ability of the Fc variants according to the invention or IgG (total IgG) to inhibit the secretion of IL2 by Jurkat cells expressing human CD64 (Jurkat-H-CD64) induced by the Raji cell line with Rituxan.
- Raji cells 50mI at 5 x 10 6 cells / ml
- Rituxan 50mI at 2mg / ml
- Jurkat H-CD64 cells 25mI at 5 x 10 6 cells / ml
- PMA phorbol ester
- the plates were centrifuged (125 g for 1 minute) and NL2 contained in the supernatant was evaluated by ELISA.
- This assay estimates the ability of the Fc variant according to the invention or IgGV to inhibit rituximab-mediated CDC activity on the Raji cell line in the presence of rabbit serum as a source of complement. Briefly, Raji cells were incubated for 30 minutes with a final concentration of 50 ng / ml of rituximab. A solution of young rabbit serum diluted 1/10 and previously incubated with the variant according to the invention or IglV (vol / vol) for 1 h at 37 ° C was added. After 1 hour of incubation at 37 ° C, the plates were centrifuged (125 g for 1 minute) and the CDC was estimated by measuring the intracellular LDH released in the culture medium.
- results were expressed as percentage inhibition and compared to IgG and negative control (Fc without Fc function), 100% corresponding to a complete inhibition of lytic activity and 0% to the control value obtained without Fc or IglV.
- the Fc variant according to the invention (A3A-184AY (HEK)) has a better inhibition of the activity of the Jurkat cells expressing CD64, of the ADCC and of the CDC, in comparison with the IVIg. .
- A3A-184AY can be effective for the treatment of pathologies involving patient autoantibodies, in particular by blocking Fc receptors on the effector cells of the patient (see FIG. 4).
- the recombinant Fc fragment can be obtained from SEQ ID NO: 14 in the same manner as that described in Example 2.
- This mutated Fc fragment can be produced by transfection into CHO-S cells with the aid of lipofection such as Freestyle Max Reagent (Thermofisher) using a vector optimized for expression in this cell line.
- the CHO-S cells are cultured in CD FortiCHO medium + 8 mM Glutamine, under conditions agitated at 135 rpm in a controlled atmosphere (8% CO 2 ) at 37 ° C. On the day before the day of transfection, the cells are seeded at a density of 6.10 5 cells / ml.
- the linearized DNA (50 ⁇ g) and 50 ⁇ l of transfection agent (AT) are pre-incubated separately in Opti-Pro SFM medium and then mixed and incubated for 20 minutes to allow the formation of the DNA complex. / AT.
- the whole is then added to a cell preparation of 1.10 6 cells / ml in a volume of 30 ml.
- transfection agents are added (Neomycin 1 g / L and Methotrexate 200 nM) to the cells.
- the cell density and viability are determined every 3-4 days and the culture volumes adapted to maintain a cell density greater than 6.10 5 cells / ml.
- the stable pools obtained are saved by freeze-thaw and productions in agitated conditions are carried out in "Fedbatch" mode for 10 days with an addition of 4g / L or 6g / L of glucose during production.
- the cells and the supernatant are separated by centrifugation. The cells are removed and the supernatant is harvested, concentrated and filtered in 0.22 ⁇ m.
- a protein A resin HiTrap protein A, GE Healthcare
- Fc receptor binding assays are performed with the following molecules:
- a wild-type Fc Fc-WT or Fc-Rec fragment obtained by digesting with papain an IgG1 produced in transgenic goat milk;
- FcRn binding is studied by competitive assay using A488 labeled Rituxan (Rituxan-A488) and Jurkat cells expressing the FcRn receptor (Jurkat-FcRn).
- the Jurkat-FcRn cells are seeded in a 96-well plate (V bottom) at a concentration of 2.10 5 cells per well. The cells are then incubated for 20 minutes at 4 ° C. with the test molecules diluted in buffer at the following final concentrations: 167 ⁇ g / ml; 83 ⁇ g / ml; 42 ⁇ g / ml; 21 ⁇ g / ml; 10 ⁇ g / ml; 5 ⁇ g / ml; 3 ⁇ g / ml; 1 ⁇ g / ml; 0 ⁇ g / ml, and simultaneously with 25 ⁇ g / ml Rituxan-A488. The cells are then washed by adding 100 ⁇ l of PBS at pH 6 and centrifuged at 1700 rpm for 3 minutes at 4 ° C. The supernatant is then removed and 300 ⁇ l of cold PBS is added at pH 6.
- the binding of Rituxan-A488 to FcRn expressed by Jurkat-FcRn cells is evaluated by flow cytometry.
- the mean fluorescence values (MFI) observed are expressed as a percentage, 100% being the value obtained with Rituxan-A488 alone and 0% the value in the absence of Rituxan-A488.
- the molecular concentrations required to induce 50% inhibition of Rituxan-A488 binding to FcRn of Jurkat-FcRn cells are calculated using "Prism Software".
- Fc A3A-184AY CHO, Fc A3A-184EY CHO and A3A-184AY-TGg variants show increased Rituxan-A488 binding inhibition (x100 compared to IVIg).
- the variants of the invention show a FcRn binding affinity equivalent to that observed with the Fc MST-HN fragment described in the literature as optimized only for FcRn (Ulrichts et al, JCI, 2018).
- Jurkat-CD64 cells are seeded in a 96-well plate (V-bottom) at a concentration of 2.10 5 cells per well. The cells are then incubated for 20 minutes at 4 ° C. with the test molecules diluted in the concentration buffer. final results: 167 pg / ml; 83 ⁇ g / ml; 42 ⁇ g / ml; 21 ⁇ g / ml; 10 ⁇ g / ml; 5 ⁇ g / ml; 3 ⁇ g / ml; 1 ⁇ g / ml; 0 ⁇ g / ml, and simultaneously with 25 ⁇ g / ml Rituxan-A488.
- the cells are then washed by adding 1 ⁇ l of PBS at pH 6 and centrifuged at 1700 rpm for 3 minutes at 4 ° C. The supernatant is then removed and 300 ⁇ l of cold PBS is added at pH 6.
- the binding of Rituxan-A488 to CD64 expressed by Jurkat-CD64 cells is evaluated by flow cytometry.
- the mean fluorescence values (MFI) observed are expressed as a percentage, 100% being the value obtained with Rituxan-A488 alone and 0% the value in the absence of rituxan-A488.
- the molecular concentrations required to induce 50% inhibition of Rituxan-A488 binding to CD64 of Jurkat-CD64 cells are calculated using "Prism Software" software.
- Human CD32 receptor binding is studied by competitive assay using Rituxan-A488 and HEK cells transfected with CD32aH and CD32aR receptors (HEK-CD32).
- the HEK-CD32 cells are seeded in a 96-well plate (V bottom) at a concentration of 2.10 5 cells per well. The cells are then incubated for 20 minutes at 4 ° C. with the test molecules diluted in buffer at the following final concentrations: 333 ⁇ g / ml; 167 ⁇ g / ml, 83 ⁇ g / ml; 42 ⁇ g / ml; 21 ⁇ g / ml; 10 ⁇ g / ml; 5 ⁇ g / ml; 3 ⁇ g / ml; 1 ⁇ g / ml; 0 ⁇ g / ml, and simultaneously with 30 ⁇ g / ml Rituxan-A488.
- the cells are then washed by adding 100 ⁇ l of PBS at pH 6 and centrifuged at 1700 rpm for 3 minutes at 4 ° C. The supernatant is then removed and 300 ⁇ l of cold PBS is added at pH 6.
- the binding of Rituxan-A488 to CD32aH and CD32aR expressed by HEK-CD32 cells is evaluated by flow cytometry.
- the mean fluorescence values (MFI) observed are expressed as a percentage, 100% being the value obtained with the Rituxan- A488_seul and 0% the value in the absence of Rituxan-A488.
- the molecular concentrations required to induce 50% inhibition of Rituxan-A488 binding to CD32aH and CD32aR of HEK-CD32 cells are calculated using "Prism Software".
- the binding to human CD16aH is studied by competitive assay using a murine anti-CD16 3G8 antibody labeled with phycoerythrin (3G8-PE) and Jurkat cells transfected with the human CD16aH receptor (Jurkat-CD16aH).
- the Jurkat-CD16aH cells are seeded in a 96-well plate (V bottom) at a concentration of 2.10 5 cells per well. The cells are then incubated for 20 minutes at 4 ° C.
- test molecules diluted in buffer at the following final concentrations: 83 ⁇ g / ml; 42 ⁇ g / ml; 21 ⁇ g / ml; 10 ⁇ g / ml; 5 ⁇ g / ml; 3 ⁇ g / ml; 1 ⁇ g / ml; 0 ⁇ g / ml, and simultaneously with 0.5 ⁇ g / ml mAb 3G8-PE.
- the cells are then washed by adding 1 ⁇ l of PBS at pH 6 and centrifuged at 1700 rpm for 3 minutes at 4 ° C. The supernatant is then removed and 300 ⁇ l of cold PBS is added at pH 6.
- the binding of mAb 3G8-PE to CD16aH expressed by Jurkat-CD16aH cells is evaluated by flow cytometry.
- the average fluorescence values (MFI) observed are expressed as a percentage, 100% being the value obtained with the mAb 3G8-PE alone and 0% the value in the absence of mAb 3G8-PE.
- the molecular concentrations required to induce 50% inhibition of mAb 3G8-PE binding to CD16aH of Jurkat-CD16aH cells are calculated using the "Prism Software" software.
- A3A-184AY CHO Fc, A3A-184EY CHO Fc and A3A-184AY_TGg variants have an increased affinity for the Fc ⁇ RIIIa (CD16a), Fc ⁇ RI (CD64) and Fc ⁇ RIla (CD32a) receptors, compared to the Fc non mutated (Fc-WT) but also compared to IVIG.
- the mutants of the invention show a very increased affinity for Fc ⁇ RIIIa (CD16a), Fc ⁇ RI (CD64) and Fc ⁇ RIla (CD32a) receptors compared to MST-HN.
- HisTag hCD16aV (R & D System) receptor is immobilized on anti-Penta-HIS Biosensors (HIS 1 K), diluted to 1 ⁇ g / ml in kinetic buffer (Pall). The molecules were tested at concentrations of 1000, 500, 250, 125, 62.5, 31, 25, 15 and 0 nM in kinetic buffer. -Loading before each sample
- association and dissociation curves (first 5s) are used to calculate the kinetic constants of association (kon) and dissociation (koff) using a 1/1 association model. KD (nM) is then calculated (kon / koff).
- Fc A3A-184AY CHO, Fc A3A-184EY CHO and A3A-184AY_TGg variants show a binding increase for the human Fc ⁇ RIIIa-V receptor (CD16a-V), and this, compared to the non-mutated Fc (Fc- WT) but also compared to IgM and Fc fragment MST-HN containing mutations M252Y / S254T / T256E / H433K / N434F.
- EXAMPLE 5 ADCC Inhibition and Activation Tests of Jurkat Cells of Variants Produced in CHO Cells and in Transgenic Goat Milk
- ADCC inhibition and Jurkat cell activation tests are performed with the following molecules:
- a wild-type Fc "Fc-Rec” or "Fc-WT” fragment obtained by digesting with papain an IgG1 produced in transgenic goat's milk,
- effector cells monoonuclear cells
- Rh-positive red cells 25 to 4 x 10 7 cells / ml final
- DAF specific substrate
- the results are expressed as a percentage of specific lysis as a function of the amount of antibody.
- the inhibition of ADCC is induced by the molecules tested (IgM, MST-HN, Fc-WT A3A-184AY CHO, A3A-184EY CHO) at concentrations of 500, 50, 5, 0.5 ⁇ g / ml. for MST-HN, Fc-WT A3A-184AY_CHO, A3A-184EY_CHO and 1500, 150, 15, 1, 5 ⁇ g / ml for IglV.
- the molecule concentrations to induce 25% or 50% inhibition were calculated with the software "Prism Software".
- A3A-184AY CHO or A3A-184EY CHO is greatly increased compared to the Fc fragment, MST-HN, containing the M252Y / S254T / T256E / H433K / N434F mutations.
- This test estimates the ability of the Fc variants according to the invention or IgIV (total IgG) to inhibit the secretion of IL2 by Jurkat cells expressing human CD64 (Jurkat-H-CD64) induced by the Raji cell line with Rituxan.
- Raji cells 50mI at 5 x 10 6 cells / ml
- Rituxan 50mI at 2mg / ml
- Jurkat H-CD64 cells 25mI at 5 x 10 6 cells / ml
- PMA phorbol ester
- the plates were centrifuged (125 g for 1 minute) and NL2 contained in the supernatant was evaluated by ELISA.
- Inhibition of IL2 secretion was induced by IgIV, Fc-WT, MST-HN or Fc variants according to the invention (A3A-184AY CHO or A3A-184EY CHO) added at 50 and 100 ⁇ g / ml.
- Fc-WT, MST-HN fragments or Fc variants according to the invention A3A-184AY CHO or A3A-184EY CHO
- 150 and 300 ⁇ g / ml for IVIG was induced by IgIV, Fc-WT, MST-HN or Fc variants according to the invention (A3A-184AY CHO or A3A-184EY CHO) added at 50 and 100 ⁇ g / ml.
- Fc-WT, MST-HN fragments or Fc variants according to the invention A3A-184AY CHO or A3A-184EY CHO
- RFC A3A-184AY CHO or A3A-184EY CHO is greatly increased compared to the MST-HN Fc fragment containing the M252Y / S254T / T256E / H433K / N434F mutations.
- the blood cell binding assays are performed with the following molecules:
- M252Y / S254T / T256E / H433K / N434F described in the literature as having a binding optimized only to the FcRn receptor (Ulrichts et al, JCI, 2018) was produced in HEK-293 cells (293-F cells, Freestyle InvitroGen),
- a wild-type Fc "Fc-Rec” or "Fc-WT” fragment obtained by digesting with papain an IgG1 produced in transgenic goat's milk,
- the labeled molecules labeled with the Alexa Fluor® marker were incubated at 65 nM (10 ⁇ g / ml for Fc in 2% CSF PBS) with target cells for 20 minutes on ice.
- NK cells Natural Killer (NK) cells labeled with anti-CD56 ("% positive NK cells”);
- the Fc ⁇ RIII receptor (CD16) was demonstrated using the anti-CD16 3G8 antibody.
- the disease was induced in mice expressing a humanized FcRn (mFcRn - / - hFcRnTg 276 heterozygous B6 gene background, The Jackson Laboratory) by injecting an anti-platelet antibody 6A6-hlgG1 (0.3pg / g body weight) by way intravenous to deplete the platelets of the mice.
- a blood test is made (number of thrombocytes) 24 hours before the injection of 6A6-hlgG1, 4h after the induction of the disease.
- IglV 1000 mg / kg
- Fc-Rec 380 and 750 mg / kg
- Fc MST-HN 190 mg / kg
- Fc A3A-184AY CHO 190 mg / kg and 380 mg / kg
- Platelet count was determined with an Advia Hematology system (Bayer). The number of platelets before the injection of antibodies was set at 100%.
- the anti-platelet antibody 6A6-hlgG1 (0.3 .mu.g / g) makes it possible to deplete 90% of the platelets.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1762217A FR3075200B1 (fr) | 2017-12-15 | 2017-12-15 | Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc |
PCT/EP2018/084970 WO2019115773A1 (fr) | 2017-12-15 | 2018-12-14 | Variants avec fragment fc ayant une affinité augmentée pour fcrn et une affinité augmentée pour au moins un récepteur du fragment fc |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3724221A1 true EP3724221A1 (fr) | 2020-10-21 |
Family
ID=62816603
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18829783.2A Pending EP3724221A1 (fr) | 2017-12-15 | 2018-12-14 | Variants avec fragment fc ayant une affinité augmentée pour fcrn et une affinité augmentée pour au moins un récepteur du fragment fc |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210214434A1 (fr) |
EP (1) | EP3724221A1 (fr) |
JP (2) | JP2021508444A (fr) |
KR (1) | KR20200098512A (fr) |
CN (1) | CN111601821B (fr) |
AU (1) | AU2018382593A1 (fr) |
BR (1) | BR112020012016A2 (fr) |
CA (1) | CA3084602A1 (fr) |
FR (1) | FR3075200B1 (fr) |
MX (1) | MX2020006013A (fr) |
WO (1) | WO2019115773A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3101640B1 (fr) | 2019-10-07 | 2024-04-12 | Lab Francais Du Fractionnement | Lignée cellulaire de monocytes humains et son utilisation en tant que modèle cellulaire de la phagocytose. |
KR102341138B1 (ko) | 2020-05-31 | 2021-12-21 | 주식회사 엑소코바이오 | 엑소좀의 막단백질 변이체를 포함하는 엑소좀 및 이의 제조방법 |
KR20220101559A (ko) | 2021-01-11 | 2022-07-19 | 주식회사 엑소코바이오 | 과발현된 Fc 수용체 또는 이의 일부를 포함하는 엑소좀 및 이의 제조방법 |
KR20220106696A (ko) | 2021-01-21 | 2022-07-29 | 주식회사 엑소코바이오 | 목적 단백질 또는 펩타이드가 융합가능한 Fc 수용체 또는 이의 일부를 포함하는 재조합 엑소좀 및 이의 용도 |
WO2023191766A1 (fr) * | 2022-03-28 | 2023-10-05 | Intervexion Therapeutics, Llc | Anticorps ayant une affinité de fcrn modifiée |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2874751B2 (ja) | 1986-04-09 | 1999-03-24 | ジェンザイム・コーポレーション | 希望する蛋白質をミルク中へ分泌する遺伝子移植動物 |
US7662925B2 (en) * | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
JP2008504002A (ja) * | 2003-11-12 | 2008-02-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 新生児Fcレセプター(FcRn)結合ポリペプチド改変体、ダイマーFc結合タンパク質、およびそれらに関連する方法 |
US20070135620A1 (en) * | 2004-11-12 | 2007-06-14 | Xencor, Inc. | Fc variants with altered binding to FcRn |
EP2233500A1 (fr) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Variantes Fc optimisées |
FR2957598B1 (fr) * | 2010-03-17 | 2015-12-04 | Lfb Biotechnologies | Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes |
JP2017520531A (ja) * | 2014-06-02 | 2017-07-27 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーLaboratoire Francais du Fractionnement et des Biotechnologies | Fc断片の産生 |
FR3024453B1 (fr) * | 2014-08-01 | 2018-06-29 | Lab Francais Du Fractionnement | Procede de production de variants ayant un fc presentant une sialylation amelioree |
FR3035879A1 (fr) * | 2015-05-07 | 2016-11-11 | Lab Francais Du Fractionnement | Mutants fc a activite fonctionnelle modifiee |
FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
FR3051794A1 (fr) * | 2016-05-31 | 2017-12-01 | Lab Francais Du Fractionnement | Anticorps pour le traitement de cancers |
FR3053688A1 (fr) * | 2016-07-06 | 2018-01-12 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Mutants fc a activite fonctionnelle amelioree |
-
2017
- 2017-12-15 FR FR1762217A patent/FR3075200B1/fr active Active
-
2018
- 2018-12-14 EP EP18829783.2A patent/EP3724221A1/fr active Pending
- 2018-12-14 AU AU2018382593A patent/AU2018382593A1/en active Pending
- 2018-12-14 KR KR1020207016305A patent/KR20200098512A/ko not_active Application Discontinuation
- 2018-12-14 CA CA3084602A patent/CA3084602A1/fr active Pending
- 2018-12-14 CN CN201880080414.6A patent/CN111601821B/zh active Active
- 2018-12-14 JP JP2020532813A patent/JP2021508444A/ja active Pending
- 2018-12-14 WO PCT/EP2018/084970 patent/WO2019115773A1/fr unknown
- 2018-12-14 BR BR112020012016-2A patent/BR112020012016A2/pt unknown
- 2018-12-14 MX MX2020006013A patent/MX2020006013A/es unknown
- 2018-12-14 US US16/772,244 patent/US20210214434A1/en active Pending
-
2023
- 2023-07-11 JP JP2023113380A patent/JP2023134604A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN111601821A (zh) | 2020-08-28 |
FR3075200B1 (fr) | 2022-12-23 |
FR3075200A1 (fr) | 2019-06-21 |
RU2020119543A (ru) | 2021-12-13 |
CA3084602A1 (fr) | 2019-06-20 |
KR20200098512A (ko) | 2020-08-20 |
AU2018382593A1 (en) | 2020-06-25 |
JP2023134604A (ja) | 2023-09-27 |
BR112020012016A2 (pt) | 2020-11-24 |
MX2020006013A (es) | 2020-08-17 |
WO2019115773A1 (fr) | 2019-06-20 |
US20210214434A1 (en) | 2021-07-15 |
JP2021508444A (ja) | 2021-03-11 |
CN111601821B (zh) | 2024-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210301028A1 (en) | Composition and methods for anti-tnfr2 antibodies | |
JP7427046B2 (ja) | Bdnfを含む融合蛋白質 | |
EP3724221A1 (fr) | Variants avec fragment fc ayant une affinité augmentée pour fcrn et une affinité augmentée pour au moins un récepteur du fragment fc | |
KR102613528B1 (ko) | RGMa 결합 단백질 및 그 사용 | |
CN111320695B (zh) | 治疗或预防认知障碍的人源化抗体、其生产方法及使用其用于治疗或预防认识障碍的剂 | |
EP3319989A2 (fr) | UTILISATION DE FRAGMENTS Fc MODIFIÉS EN IMMUNOTHÉRAPIE | |
JPWO2016208696A1 (ja) | Bdnfを含む融合蛋白質 | |
TW202003570A (zh) | 抗trem-1抗體及其用途 | |
JP2024503212A (ja) | ネコ科動物抗体の定常領域における変異 | |
JP2020533362A (ja) | エクト酵素に結合する重鎖抗体 | |
JP2022514187A (ja) | IVIGの代替のための多量体ハイブリッドFc蛋白質 | |
JP2023551194A (ja) | ウシ科動物抗体バリアント | |
CN116802205A (zh) | 犬抗体恒定区中的突变 | |
RU2820162C2 (ru) | Варианты с fc-фрагментом, обладающие повышенной аффинностью к fcrn и повышенной аффинностью по меньшей мере к одному рецептору fc-фрагмента | |
WO2019129848A1 (fr) | Procédé de purification d'anticorps à partir de lait brut | |
JP2023504974A (ja) | 抗tirc7抗原結合タンパク質 | |
EA040482B1 (ru) | Гуманизированное антитело для лечения или предотвращения когнитивных расстройств, способ его получения и агент для лечения или предотвращения когнитивных расстройств с его применением |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200615 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: MEADE, HARRY Inventor name: MONNET, CELINE Inventor name: MONDON, PHILIPPE |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230503 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230502 |